Ernexa Therapeutics Inc. (ERNA) Convertible Debt (2023 - 2024)
Ernexa Therapeutics' (ERNA) quarterly Convertible Debt came in at $32.0 million in Q3 2024, up 828.07% YoY from $3.5 million in Q4 2023, and up 260.17% on a QoQ basis from $8.9 million in Q2 2024.
Ernexa Therapeutics Inc. (ERNA) Convertible Debt (2023 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 2 years of Convertible Debt data on file, last reported at $32.0 million in Q3 2024.
- Quarterly Convertible Debt rose 828.07% year-over-year to $32.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $32.0 million (up 828.07% YoY) and the FY2023 annual result came in at $6.8 million, changed N/A from the prior year.
- Convertible Debt improved to $32.0 million in Q3 2024, from $8.9 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $32.0 million in Q3 2024 to a low of $3.5 million in Q3 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 32.04 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | 8.01 Mn |
| Dec 31, 2023 | 6.77 Mn |
| Sep 30, 2023 | 3.45 Mn |